{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-064429","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.331335+00:00","generated_at":"2026-05-22T12:46:38.341192+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spruce Biosciences Q1 net loss $14.0M; cash runway to end 2025; TA-ERT BLA in 1H 2026","bullets":["Q1 2025 net loss $14.0M vs $11.6M YoY; R&D includes $5.7M for SPR202 acquisition.","Cash and equivalents $25.6M, expected to fund current operating plan through end of 2025.","TA-ERT for MPS IIIB: BLA submission to FDA expected in 1H 2026; FDA confirmed HS-NRE as surrogate endpoint for accelerated approval.","Tildacerfont Phase 2 TAMARIND MDD study topline results expected 1H 2026; HMNC funding and conducting study.","Stock now trades on OTC Pink under SPRB after NYSE delisting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-064429","json":"https://secwatch.observer/filing/0000950170-25-064429.json","markdown":"https://secwatch.observer/filing/0000950170-25-064429.md","text":"https://secwatch.observer/filing/0000950170-25-064429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025064429/0000950170-25-064429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025064429/sprb-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:46:38.341192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}